Disease · EFO_0000551
intracranial hemorrhage
6 sourcesdiseases-2026-09-18-0.1.0
Cite this record
ConductScience Library. intracranial hemorrhage. Diseases, record EFO_0000551. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0000551
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
Brain Hemorrhage, Brain Hemorrhages, HEMORRHAGE INTRACRANIAL, Hemorrhage, Brain, Hemorrhage, Posterior Fossa, Hemorrhages, Brain, Hemorrhages, Intracranial, Hemorrhages, Posterior Fossa, INTRACRANIAL HEMORR NOS, Intracranial Hemorrhages, Intracranial haemorrhage, Intracranial haemorrhage NOS, Intracranial hemorrhage (disorder), Intracranial hemorrhage, NOS, Posterior Fossa Hemorrhage, Posterior Fossa Hemorrhages, Unspecified intracranial hemorrhage, intracranial hemorrhage NOS (disorder)
- Open Targets
Drugs19
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TRANEXAMIC ACID | CHEMBL877 | Small molecule | Phase 3 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| TENECTEPLASE | CHEMBL2108791 | Enzyme | Phase 3 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ABCIXIMAB | CHEMBL1201584 | Antibody | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| BLOOD, WHOLE | CHEMBL2108414 | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets | |
| CAFFEINE CITRATE | CHEMBL1200569 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| WARFARIN | CHEMBL1464 | Small molecule | Phase 3 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| HUMAN IMMUNOGLOBULIN G | CHEMBL1201599 | Phase 2 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets | |
| BUMETANIDE | CHEMBL1072 | Small molecule | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| EPTACOG ALFA (ACTIVATED) | CHEMBL2108334 | Protein | Phase 1 | ClinicalTrials.gov | 1 | 1 | 1 | Drugs and targets |
| THROMBIN | CHEMBL2108110 | Phase 1 | ClinicalTrials.gov | 1 | 1 | 0 | Drugs and targets |
1 to 10 of 19
See all 19 drugsTargets23
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| F10 | Coagulation factor X | 2 | Coagulation factor X exogenous protein; Coagulation factor X inhibitor | Unknown | https://conductscience.org/library/genes/2159 | Drugs and targets |
| F2 | Prothrombin | 2 | Thrombin exogenous protein; Thrombin inhibitor | Unknown | https://conductscience.org/library/genes/2147 | Drugs and targets |
| F7 | Coagulation factor VII | 2 | Coagulation factor VII exogenous protein | Phase 1 | https://conductscience.org/library/genes/2155 | Drugs and targets |
| PTGS1 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5742 | Drugs and targets |
| PTGS2 | Cyclooxygenase | 2 | Cyclooxygenase inhibitor | Unknown | https://conductscience.org/library/genes/5743 | Drugs and targets |
| ADORA1 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/134 | Drugs and targets |
| ADORA2A | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/135 | Drugs and targets |
| ADORA2B | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/136 | Drugs and targets |
| ADORA3 | Adenosine receptor | 1 | Adenosine receptor antagonist | Phase 3 | https://conductscience.org/library/genes/140 | Drugs and targets |
| CD38 | ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase 1 | 1 | Lymphocyte differentiation antigen CD38 inhibitor | Early phase 1 | https://conductscience.org/library/genes/952 | Drugs and targets |
1 to 10 of 23
See all 23 targetsTrials20
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01990768 | Prehospital Tranexamic Acid Use for Traumatic Brain Injury | Phase 2 | 967 | 2019-01-14 | Traumatic Brain Injury | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov |
| NCT01654445 | TNK-tPA Evaluation for Minor Ischemic Stroke With Proven Occlusion | Phase 2 | 50 | 2020-11-25 | Ischemic Stroke | TENECTEPLASE | Its record names the disease | ClinicalTrials.gov |
| NCT01947959 | Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Germany) | 665,533 | Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation, Acute Coronary Syndrome | RIVAROXABAN | Its record names the disease | ClinicalTrials.gov | ||
| NCT02468102 | Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden) | 99,999 | Acute Coronary Syndrome, Venous Thrombosis, Pulmonary Embolism, Atrial Fibrillation | RIVAROXABAN | Its record names the disease | ClinicalTrials.gov | ||
| NCT01402882 | Clinical Randomisation of an Antifibrinolytic in Significant Head Injury | Phase 3 | 12,737 | Traumatic Brain Injury | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT05548777 | Andexanet Alfa and 4F-PCC Use in Patients Hospitalised With an Anticoagulant-related Major Bleed | 5,480 | Anticoagulant-related Major Bleed | ANDEXANET ALFA | Its record names the disease | ClinicalTrials.gov | ||
| NCT04521881 | Clinical Randomisation of an Anti-fibrinolytic in Symptomatic Mild Head Injury in Older Adults | Phase 3 | 5,000 | Traumatic Brain Injury | TRANEXAMIC ACID | Its record names the disease | ClinicalTrials.gov | |
| NCT06322953 | Timing to Restart Direct Oral Anticoagulants After Traumatic Intracranial Haemorrhage | Phase 3 | 1,084 | Traumatic Intracranial Haemorrhage | WARFARIN | Its record names the disease | ClinicalTrials.gov | |
| NCT00073372 | A Study of Effectiveness and Safety of Abciximab in Patients With Acute Ischemic Stroke (AbESTT-II) | Phase 3 | 808 | Cerebrovascular Accident, Brain Ischemia, Acute Disease | ABCIXIMAB | Its record names the disease | ClinicalTrials.gov | |
| NCT06868511 | Neuronavigation-assisted Stereotactic Puncture With Tenecteplase for Acute Intracerebral Hemorrhage | Phase 3 | 732 | Deep Intracerebral Hemorrhage (ICH) | TENECTEPLASE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 20
See all 20 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: Number of Patients With Serious Bleeding Events | 0 of 25 | 1 of 25 | 50 | NCT01654445 | Trial comparisons |
| Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: deaths from any cause | 0 of 25 | 1 of 25 | 50 | NCT01654445 | Trial comparisons |
| Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: serious adverse events | 0 of 25 | 1 of 25 | 50 | NCT01654445 | Trial comparisons |
| Tenecteplase 0.1 mg/kg vs Tenecteplase 0.25 mg/kg: Number of Patients With Recanalization 4-8 Hours Post-treatment | 9 of 23 | 12 of 23 | 46 | NCT01654445 | Trial comparisons |
Papers from its trials20
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 25677596 | RESULT | 1 | PubMed |
| 18032739 | RESULT | 1 | PubMed |
| 42754280 | DERIVED | 1 | PubMed |
| 40490870 | DERIVED | 1 | PubMed |
| 39524040 | DERIVED | 1 | PubMed |
| 39502454 | DERIVED | 1 | PubMed |
| 39226704 | DERIVED | 1 | PubMed |
| 38685481 | DERIVED | 1 | PubMed |
| 37870112 | DERIVED | 1 | PubMed |
| 37807179 | DERIVED | 1 | PubMed |
1 to 10 of 20
See all 20 papers from its trialsData dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/EFO_0000551
GET https://conductscience.org/api/diseases/v1/EFO_0000551/targets?page=2